Back to Pfizer

Pfizer News

PFE

Pfizer CFO Transition — Reaffirms 2026 Guidance

Pfizer (PFE) CFO Dave Denton to depart; Cecile Guegan named interim CFO. Company reaffirms 2026 guidance. Key context for investors.

18 June 2026PFIZER INC
PFE

PFE: Pfizer CFO Dave Denton to Depart

Pfizer (PFE) CFO Dave Denton to depart; Cecile Guegan named interim CFO. Key investor implications for capital allocation, R&D and cost-savings.

18 June 2026PFIZER INC
PFE

Pfizer Revises 2025 Revenue Guidance

Pfizer lowers its 2025 revenue outlook and issues 2026 guidance; investors weigh pipeline, cost savings, and pricing agreements.

16 December 2025PFIZER INC
PFE

Pfizer Reports Approvals and Phase 3 Wins

Pfizer (PFE) announces 4 regulatory approvals and 8 positive Phase 3 readouts in 2025; pipeline, financials, and investor risks summarized.

4 November 2025PFIZER INC
PFE

Pfizer Q3 2025: Revenue Down, EPS Guidance Raised

Pfizer (PFE) Q3 2025 revenue and earnings fell; net income $3.54B ($0.62). Company raised full‑year EPS guidance citing cost savings and pipeline progress.

4 November 2025PFIZER INC
PFE

Pfizer (PFE) Agrees U.S. Pricing Deal; Buys Metsera

Pfizer (PFE) secures a U.S. drug pricing agreement and acquires Metsera for $4.9B, bolstering its obesity pipeline and altering margin and capital priorities.

4 November 2025PFIZER INC
All news